Clinical Trials Logo

Bioequivalence clinical trials

View clinical trials related to Bioequivalence.

Filter by:

NCT ID: NCT04466176 Completed - Bioequivalence Clinical Trials

A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Start date: July 1, 2020
Phase: Phase 1
Study type: Interventional

Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder

NCT ID: NCT04462822 Completed - Bioequivalence Clinical Trials

A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Start date: August 24, 2020
Phase: Phase 1
Study type: Interventional

Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder

NCT ID: NCT04460820 Completed - Bioequivalence Clinical Trials

A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

Start date: July 4, 2019
Phase: N/A
Study type: Interventional

A Randomized,Open-label, Single-Dose,Two-Cycle,Cross- Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection Under Advanced Breast Cancers.

NCT ID: NCT04444986 Completed - Bioequivalence Clinical Trials

Bioequivalence Study of Favir 200 mg Film Tablet Kocak Under Fasting Conditions

Start date: June 5, 2020
Phase: Phase 1
Study type: Interventional

A single dose of Reference product containing 200 mg favipiravir and a single dose of Test product containing 200 mg favipiravir or vice versa; administered with 240 mL of water at room temperature, in each period under fasting conditions with current pandemic precautions.

NCT ID: NCT04440423 Completed - Bioequivalence Clinical Trials

Bioavailability of Clotiazepam 5 mg With Regards to Reference Product

Start date: March 11, 2020
Phase: Phase 1
Study type: Interventional

This Pivotal study will investigate the bioavailability in fasting women of 1 Tablet formulations containing Clotiazepam 5 mg. The Pivotal study will be performed at a single site with 30 subjects. Participants will take 1 Tablet of the test product and reference product in 2 periods and 2 sequences (either test after reference or reference after test). There will be a washout of at least 7 days between each study period.

NCT ID: NCT04422028 Completed - Bioequivalence Clinical Trials

Bioavailability of Desogestrel 0.075 mg Tablets With Regards to Reference Product

Start date: January 11, 2020
Phase: Phase 1
Study type: Interventional

This Pivotal study investigated the bioavailability in women of 2 tablet formulations containing Desogestrel 0.075 mg. The Pivotal study was performed at a single site with 30 subjects. Participants took 2 tablets of the test product and reference product in 2 periods and 2 sequences (either test after reference or reference after test). There was a washout of 14 days between each study period.

NCT ID: NCT04411953 Completed - Bioequivalence Clinical Trials

Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fed Conditions

Start date: November 15, 2019
Phase: Phase 1
Study type: Interventional

The purpose on this study was to determine whether the test product, Haloperidol Tablets, 2 mg (Cycle Pharmaceuticals Ltd), and the reference product, Haloperidol Tablets, United States Pharmacopeia (USP), 2 mg (Mylan Pharmaceuticals Inc.) are bioequivalent under fed conditions.

NCT ID: NCT04411940 Completed - Bioequivalence Clinical Trials

Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fasting Conditions

Start date: November 15, 2019
Phase: Phase 1
Study type: Interventional

The purpose on this study was to determine whether the test product, Haloperidol Tablets, 2 mg (Cycle Pharmaceuticals Ltd), and the reference product, Haloperidol Tablets, United States Pharmacopeia (USP), 2 mg (Mylan Pharmaceuticals Inc.) are bioequivalent.

NCT ID: NCT04407000 Completed - Bioequivalence Clinical Trials

Bioequivalence Study of Favipiravir 200 mg Film Tablet (World Medicine, Turkey) Under Fasting Conditions

Favipiravir
Start date: June 23, 2020
Phase: Phase 1
Study type: Interventional

A single dose of Reference product containing 200 mg favipiravir and a single dose of Test product containing 200 mg favipiravir or vice versa; administered with 240 mL of water at room temperature, in each period under fasting conditions with current pandemic precautions.

NCT ID: NCT04406194 Completed - Bioequivalence Clinical Trials

Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions

Favipiravir
Start date: May 14, 2020
Phase: Phase 1
Study type: Interventional

A single dose of Reference product containing 200 mg favipiravir and a single dose of Test product containing 200 mg favipiravir or vice versa; administered with 240 mL of water at room temperature, in each period under fasting conditions with current pandemic precautions.